Tetraphase Pharmaceuticals (NASDAQ: TTPH) is one of 109 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Tetraphase Pharmaceuticals to related companies based on the strength of its earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.
Valuation & Earnings
This table compares Tetraphase Pharmaceuticals and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Tetraphase Pharmaceuticals||$5.14 million||-$77.48 million||-2.21|
|Tetraphase Pharmaceuticals Competitors||$8.39 billion||$1.12 billion||156.99|
Tetraphase Pharmaceuticals’ competitors have higher revenue and earnings than Tetraphase Pharmaceuticals. Tetraphase Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares Tetraphase Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Tetraphase Pharmaceuticals Competitors||-2,482.85%||-61.40%||-8.41%|
Institutional & Insider Ownership
42.8% of Tetraphase Pharmaceuticals shares are owned by institutional investors. Comparatively, 43.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 5.5% of Tetraphase Pharmaceuticals shares are owned by company insiders. Comparatively, 11.7% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk & Volatility
Tetraphase Pharmaceuticals has a beta of 2.52, meaning that its share price is 152% more volatile than the S&P 500. Comparatively, Tetraphase Pharmaceuticals’ competitors have a beta of 34.65, meaning that their average share price is 3,365% more volatile than the S&P 500.
This is a summary of current ratings and price targets for Tetraphase Pharmaceuticals and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Tetraphase Pharmaceuticals Competitors||858||3773||6716||178||2.54|
Tetraphase Pharmaceuticals presently has a consensus price target of $17.00, suggesting a potential upside of 169.41%. As a group, “Pharmaceuticals” companies have a potential upside of 25.70%. Given Tetraphase Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts plainly believe Tetraphase Pharmaceuticals is more favorable than its competitors.
Tetraphase Pharmaceuticals competitors beat Tetraphase Pharmaceuticals on 8 of the 12 factors compared.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.